Kim Kelderman, Chief Executive Officer and Director of BIO-TECHNE Corp, filed an amended statement of changes in beneficial ownership on November 2, 2026, covering multiple transactions in common stock, performance stock options, performance restricted stock units, and restricted stock units dated August 15, 2026.

Key Highlights

  • Shares acquired via vesting: Kelderman acquired 21,736 shares of common stock through an M-coded transaction at $0, bringing direct holdings to 93,849 shares before subsequent dispositions.
  • Tax withholding disposition: 10,955 shares were disposed of (code F) at $72.40 per share on August 15, 2026, leaving direct beneficial ownership of 82,894 shares.
  • Performance options partially vested, remainder forfeited: The Board authorized discretionary vesting of 1,837 options (exercise price $84.61) and 1,996 options (exercise price $68.54); the remaining performance options in each grant were forfeited.
  • Performance RSUs partially vested, remainder forfeited: The Board authorized discretionary vesting of 683 and 725 performance RSUs respectively; all remaining performance RSUs in those grants were forfeited, leaving zero balance in each.
  • New RSU grants received: Kelderman received 8,543 restricted stock units vesting August 15, 2026 (with 8,544 vesting August 15, 2027), and 11,785 RSUs vesting on each of August 15, 2026 and August 15, 2027, plus 11,784 vesting August 15, 2028.
  • Amendment to original filing: This filing amends an original statement filed August 18, 2026, with the earliest transaction date of August 15, 2026.

Board-Authorized Vesting and Equity Changes for Bio-Techne's CEO

According to the filing, all transactions reported occurred on August 15, 2026, and were tied to Bio-Techne's equity compensation arrangements for its Chief Executive Officer. Bio-Techne (NASDAQ:TECH) is identified in the filing as the issuer. The company's ticker symbol is listed as TECH on the cover of the amended statement. Kelderman is identified both as a Director and as Chief Executive Officer of the company, which develops and manufactures biotechnology products including proteins, antibodies, and related research tools used in life-science research and diagnostics.

The filing discloses that the Bio-Techne Board of Directors exercised discretionary authority on August 15, 2026, to authorize partial vesting of performance-based awards. For performance stock options, the Board approved vesting of 1,837 options at an exercise price of $84.61 and 1,996 options at an exercise price of $68.54, while the remaining performance options in each series were forfeited. For performance RSUs, the Board approved vesting of 683 units from one grant and 725 units from a second grant, with the remainder forfeited in each case. Each restricted stock unit is described as "a contingent right to receive one share of Bio-Techne common stock," according to the filing's explanation of responses.

In addition to the performance-based awards, the filing reports that 8,543 time-based restricted stock units vested on August 15, 2026, with 8,544 scheduled to vest on August 15, 2027. A separate RSU grant provides for 11,785 units vesting on each of August 15, 2026 and August 15, 2027, and 11,784 units vesting on August 15, 2028. The amended filing was signed by Andrew Nick as attorney-in-fact for Kim Kelderman pursuant to a previously filed power of attorney, and was submitted on November 2, 2026.

What Was Disclosed

The amended filing reports Kim Kelderman's equity transactions at BIO-TECHNE Corp on August 15, 2026, covering the vesting and partial forfeiture of performance options and performance RSUs, the vesting of time-based RSUs, a tax-related share disposition at $72.40, and resulting direct beneficial ownership of 82,894 common shares.